The most recent developments in diagnostic and therapeutic aspects of Gliomas (Glioblastoma) in
the brain are presented. The importance of personalized medicine and clinical validation for
targeted therapy are discussed. The identification of various types of biomarkers is included.
The identification and validation of brain cancer (glioblastoma) genes are discussed. Role of
cancer stem cells in the initiation progression and persistence of malignant gliomas is
explained. The use of surgical resection chemotherapy (e.g. temozolomide) immunotherapy and
radiotherapy for malignant glioblastoma are pointed out. Standard (established) as well as
newer imaging modalities (proton magnetic resonance spectroscopy) are discussed.